Scienza e Tecnologia
MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports
As the Paris 2024 Summer Olympics commence, Prof. Pitsiladis, invited by the World Olympians Association (WOA), will showcase his research and participate in a panel discussion, as part of Hong Kong Baptist University's two-day program during the games, taking place on 29 July at OLY House Paris 2024 @ Caisse d'Epargne. Additionally, MGI will exhibit its cutting-edge portable DNBSEQ-E25 sequencer, ultra-high speed DNBSEQ-G99 platform, and AlphaTool automated pipetting robot at the venue, offering Olympians from around the world a glimpse of the advanced technologies.
On July 22 , Prof. Pitsiladis, in conjunction with MGI and other international researchers, published a perspective article titled "Practical steps to develop a transcriptomic test for blood doping" on . Outlining considerations for developing a transcriptomic test for blood doping, the article serves to assist international research and anti-doping centers in adopting transcriptomic testing in compliance with the World Anti-Doping Agency.
"We are proud to empower valuable research into sports performance and anti-doping testing through omics and showcase our technologies at one of the most important events in sports," said
Duncan Yu , President of MGI. "With intelligent innovation at the heart of MGI, we are committed to applying our technologies to enable significant advancements and support groundbreaking applications in this field."
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
Logo - https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mgi-and-hkbu-collaborate-on-advanced-sequencing-technology-to-combat-doping-in-sports-302207425.html